STRO stock icon

Sutro Biopharma
STRO

$4.06
3.19%

Market Cap: 332M

 

About: Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers.

Employees: 300

0
Funds holding %
of 6,702 funds
0
Analysts bullish %
of 12 analysts
News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

286% more call options, than puts

Call options by funds: $54K | Put options by funds: $14K

200% more funds holding in top 10

Funds holding in top 10: 1 [Q4 2023] → 3 (+2) [Q1 2024]

53% more repeat investments, than reductions

Existing positions increased: 49 | Existing positions reduced: 32

26% more capital invested

Capital invested by funds: $239M [Q4 2023] → $302M (+$63M) [Q1 2024]

18% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 17

3% more funds holding

Funds holding: 114 [Q4 2023] → 117 (+3) [Q1 2024]

5.76% less ownership

Funds ownership: 91.3% [Q4 2023] → 85.54% (-5.76%) [Q1 2024]

Research analyst outlook

12 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$8
97%
upside
Avg. target
$11.83
191%
upside
High target
$18
343%
upside

12 analyst ratings

12 positive
100%
neutral
0%
negative
0%
Oppenheimer
Jay Olson
146%upside
$10
Outperform
Maintained
15 May 2024
Wedbush
David Nierengarten
97%upside
$8
Outperform
Reiterated
14 May 2024
HC Wainwright & Co.
Andrew Fein
196%upside
$12
Buy
Reiterated
14 May 2024
B of A Securities
Tazeen Ahmad
196%upside
$12
Buy
Initiated
8 May 2024
Piper Sandler
Edward Tenthoff
171%upside
$11
Overweight
Reiterated
3 Apr 2024

Financial journalist opinion